Vir Biotechnology’s Promising Pipeline and Strong Financial Position Justify Buy Rating

Michael Ulz, an analyst from Morgan Stanley, maintained the Buy rating on Vir Biotechnology (VIR – Research Report). The associated price target remains the same with $20.00.

Michael Ulz has given his Buy rating due to a combination of factors related to Vir Biotechnology’s promising pipeline developments. The company is making significant progress with its T-cell engager (TCE) platform, showcasing positive initial data for VIR-5500 and VIR-5818, which are advancing in Phase 1 dose escalation trials. These trials have demonstrated promising activity and a wide therapeutic index, suggesting potential for future success.
Additionally, Vir Biotechnology is on track to initiate a Phase 1 study for VIR-5525 in solid tumors in the first half of 2025, further expanding its TCE platform. The company is also preparing to start Phase 3 ECLIPSE clinical trials for HDV in the same timeframe, which are expected to support marketing applications in the US and Europe. With a strong cash position of approximately $1.1 billion, Vir is well-positioned to continue its research and development efforts, reinforcing the Buy rating from Michael Ulz.